Integrated BioPharma, Inc.: Integrated BioPharma Reports Results for its Quarter and Fiscal Year Ended June 30, 2026
Integrated BioPharma, Inc. (INBP) reported a 31% revenue decline to $9.8M for Q2 2026 and a 19% drop to $43.9M for the fiscal year, with net losses of $1.4M and $2.8M, respectively. The company attributed the decrease to reduced revenue from its two largest customers, according to its executives.
How this was made
The 30-second read
Why it matters
The earnings miss underscores challenges in its two largest customers, which together accounted for ~90% of revenue, raising concerns about customer concentration.
Market read
The earnings decline may trigger short‑term selling pressure on INBP, while the broader market remains largely unaffected.
What to watch
Potential cost‑cutting measures or upcoming product launches not disclosed in the release.
Background
Integrated BioPharma, an OTCQX listed contract manufacturer of vitamins and supplements, issued its FY 2026 earnings release.
Ticker impact
Integrated BioPharma reported Q2 and FY 2026 results showing 31% revenue decline and a net loss of $2.8M, a material deterioration from the prior year.
downward pressure in the near term
The company posted a sizable revenue decline and swung to a net loss, indicating weaker demand and higher risk.
Market effects
Highlights weakness in the nutraceutical contract‑manufacturing segment.
Limited to U.S. OTC market; no broader regional effect.
Minimal, as the company is a micro‑cap with niche exposure.
Counterpoint
If the revenue decline is temporary and the company secures new contracts, the stock could rebound.
Key entities
- CompanyIntegrated BioPharma, Inc.
OTCQX listed manufacturer of nutraceutical products.
- ExecutiveRiva Sheppard
Co‑Chief Executive Officer of Integrated BioPharma.
- ExecutiveChristina Kay
Co‑Chief Executive Officer of Integrated BioPharma.
